Trulieve Cannabis Corp. (CSE:TRUL) shares have had a horrible month, losing 56% after a relatively good period beforehand. Longer-term shareholders would now have taken a real hit with the stock declining 4.6% in the last year.
Although its price has dipped substantially, you could still be forgiven for feeling indifferent about Trulieve Cannabis’ P/S ratio of 0.9x, since the median price-to-sales (or “P/S”) ratio for the Pharmaceuticals industry in Canada is also close to 0.8x. While this might not raise any eyebrows, if the P/S ratio is not justified investors could be missing out on a potential opportunity or ignoring looming disappointment.
Check out our latest analysis for Trulieve Cannabis
What Does Trulieve Cannabis’ Recent Performance Look Like?
With revenue growth that’s inferior to most other companies of late, Trulieve Cannabis has been relatively…
